In honor of Stomach Cancer Awareness Month Martha Raymond, Executive Director of the GI Cancers Alliance, interviews Steve Melen, a Stomach Cancer survivor and patient advocate, about his story with Stomach Cancer.
The GI Cancers Alliance welcomes your thoughts on clinical trial participation in the midst of COVID-19.
Bristol Myers Squibb today announced that Opdivo® (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
This webinar, will provide up-to-the-minute information about changes to health insurance and employment, including new options for paid sick leave, paid family leave, and unemployment benefits.
Bayer and NeoGenomics launch the Test4TRK™ Program to provide genomic cancer testing at no cost for people living with advanced thyroid and colorectal cancers.
Personalized, evidence-based nutrition support available 24/7 “on demand” to help cancer patients stay well-nourished and manage nutrition-related treatment side effects.
We understand that during this time of uncertainty due to the COVID-19 Coronavirus pandemic, the gastrointestinal cancer community has many questions and concerns.
Bristol Myers Squibb Company today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S.
Since 2006, the Mesothelioma Center has raised awareness for asbestos exposure & helped thousands of families find treatment & compensation.
The Chan Zuckerberg Initiative (CZI) announced that the Fibrolamellar Cancer Foundation (FCF) is among a select group of patient-led rare.